Dysregulation of microRNAs (miRNAs) plays an important role in the pathogenesis of chronic lymphocytic leukemia (CLL). The Eμ-TCL1 transgenic mouse develops a form of leukemia that is similar to the aggressive type of human B-CLL, and this valuable model has been widely used for testing novel therapeutic approaches. Here, we adopted this model to investigate the potential effects of miR-26a, miR-130an and antimiR-155 in CLL therapy. Improved delivery of miRNA molecules into CLL cells was obtained by developing a novel system based on lipid nanoparticles conjugated with an anti-CD38 monoclonal antibody. This methodology has proven to be highly effective in delivering miRNA molecules into leukemic cells. Short-and long-term experiments showed that miR-26a, miR-130a and anti-miR-155 increased apoptosis after in vitro and in vivo treatment. Of this miRNA panel, miR-26a was the most effective in reducing leukemic cell expansion. Following long-term treatment, apoptosis was readily detectable by analyzing cleavage of PARP and caspase-7. These effects could be directly attributed to miR-26a, as confirmed by significant downregulation of its proven targets, namely cyclin-dependent kinase 6 and Mcl1. The results of this study are relevant to two distinct areas. The first is related to the design of a technical strategy and to the selection of CD38 as a molecular target on CLL cells, both consenting efficient and specific intracellular transfer of miRNA. The original scientific finding inferred from the above approach is that miR-26a can elicit in vivo anti-leukemic activities mediated by increased apoptosis.
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is the most common B-cell malignancy in Western countries. CLL lymphocytes resemble memory B cells with a mature phenotype. 1 This leukemia is characterized by the accumulation of CD5+ B lymphocytes in the blood, spleen, liver, lymph nodes and bone marrow. Despite its morphological homogeneity, CLL is a clinically heterogeneous disease [2] [3] [4] with a number of adverse factors that affect the clinical course, including stage 5 ; CD38 positivity; unmutated variable region of the immunoglobulin heavy chain gene (IGHV) 6 ; ZAP70 positivity 7 ; karyotype aberrations 8 ; and TP53, NOTCH1, SF3B1 and other gene mutations. 9, 10 Despite the progress in chemoimmunotherapy, CLL remains an incurable disease. 11 To help decipher the pathogenic mechanisms of disease and evaluate the efficacy and mechanisms of action of novel therapies, researchers have developed mouse models that resemble human CLL. 12, 13 The Eμ-TCL1 transgenic (TCL1-tg) mouse develops a leukemia that is highly similar to the aggressive form of human CLL. [14] [15] [16] An important feature of TCL1 overexpression is that it exhibits 100% disease penetrance. At the age of 16-20 months, these mice show a B-CLL-like disease characterized by spleno-and hepatomegaly associated with high counts of white blood cells. Leukemias are characterized by clonal expansion of B cells with a B220+/IgM+/CD5+ immunophenotype, unmutated IGHV, increased proliferation and enhanced AKT phosphorylation. Tumor cells in TCL1-tg mice have wild-type (WT) p53 and initially respond to fludarabine treatment. 17 Notably, leukemic cells from a TCL1-tg donor can be transplanted by intraperitoneal (i.p.) or intravenous injection into syngeneic WT or immunodeficient mice (for example, severe combined immunodeficiency) to accelerate the disease course and generate genetically homogeneous populations of leukemic cells, which better allows for systematic comparison of novel therapies.
MicroRNAs (miRNAs) play a central role in the pathogenesis of CLL. They regulate gene expression at the post-transcriptional level by targeting messenger RNA for degradation or translational inhibition and thus can modulate several biological processes. As a consequence of their deregulation, miRNAs may act as oncogenes or tumor suppressors. 18 The discovery of the involvement of miRNAs in human cancer originated from studies of CLL. 19 miR-15a and miR-16-1 were found within the minimal region of deletion at chromosome 13q, the most frequent genetic alteration found in human CLL. Deletion of miR-15a/miR-16-1 in a knockout mouse model was shown to confer predisposition to the development of an indolent form of leukemia similar to human CLL. 20 BCL2 was a target of these miRNAs; thus, their loss eliminated control over BCL2 expression. 21 It is notable that venetoclax, a highly active and recently approved drug against CLL, was designed to inhibit BCL2 activity. 22 A prognostic signature consisting of a panel of aberrantly expressed miRNAs has been identified in CLL. 23 Other important miRNAs in human CLL include miR-34a, which, being an effector of the p53 protein, is strongly downregulated in 17p-CLL cases, or miR-181b, which is downregulated during disease progression. [24] [25] [26] In a more recent comprehensive study, we found that a number of miRNAs are deregulated in CLL. 27 miRNAs were differentially expressed between CLL cells and mature antigen-experienced B cells, or correlated to specific pathological features (IGHV somatic mutations or specific cytogenetic aberrations) or clinical parameters, such as time to first treatment. 27 These studies established the groundwork from which miRNA-based therapies, either by restoring or repressing miRNA activity, could be designed and tested. We have already investigated miR-181b as a potential therapeutic molecule against leukemias of the TCL1-tg mouse model. 28 The study proved that this miRNA induced a measurable anti-leukemic effect. However, an improvement in delivery methods was suggested.
Here, we used the Eμ-TCL1FL mouse model 15 to test the antileukemic activity of various miRNA mimics or anti-miRNA oligonucleotides (AMOs). To increase in vivo delivery, we developed a lipopolyplex formulation that included anti-CD38-conjugated lipid nanoparticles (CD38-NPs), which considerably increased the specificity for hCD38+ leukemic cells of this mouse model. The choice of CD38 as a molecule to target CLL cells was guided by its known importance in CLL, 29 as well as its structural characteristics 30 and the evidence of its antibody-mediated internalization. 31 
RESULTS
Leukemic cells of the Eμ-TCL1FL transgenic mouse are CD38+ Leukemic cells of the Eμ-TCL1FL transgenic mouse or transplanted into syngeneic FVB mice are characterized by B220+/CD5dim surface markers. 28 Here, we evaluated the expression of CD38. To this end, the splenic lymphocyte population from transgenic or transplanted FVB mice with a high level of disease was first sorted on the basis of physical parameters, and the B220+/CD5dim leukemic population was identified; finally, the lymphocytes within the B220+/CD5dim gate were analyzed for CD38 expression, showing that more than 98% of the cells were positive (Figure 1 ). This analysis not only confirmed that the TCL1-tg model exhibits an immunophenotype typical of an aggressive form of B-CLL characterized by high expression of CD38, but it also provided a way to specifically target leukemic cells.
Lipid nanoparticles conjugated with anti-CD38 antibodies can efficiently deliver miRNAs into CLL cells On the basis of this evidence, we developed lipid nanoparticles conjugated with anti-CD38 antibodies (CD38-NPs) to improve the Figure 1 . In the Eμ-TCL1FL TG mouse, the leukemic population (B220+/CD5dim) is CD38+. Cells were isolated from the spleen of an adult Eμ-TCL1FL transgenic mouse (upper panels) or a transplanted FVB-TCL1 mouse (lower panels). The left panels show the lymphocyte population, the middle panels the B220+/Cd5dim leukemic population. The right panels show the CD38+ lymphocytes within the B220+/CD5dim population: more than 98% of the cells are positive.
efficiency of in vivo miRNA delivery into leukemic cells. The lipid NP-miRNAs were synthesized as described. 32 We investigated the efficiency of CD38-NPs both in vitro and in vivo. In vitro, we tested whether CD38-NPs could deliver mature miRNAs into murine TCL1-tg leukemic cells. We transfected cells with miR-181b mimics, miRNA that we had previously investigated. 28 Twenty-four hours after transfection, cells were collected for RNA extraction and the levels of miR-181b measured (Supplementary Figure 1) . These in vitro results indicated that CD38-NPs could efficiently deliver small RNA into leukemic cells and were approximately two-fold more efficient than unconjugated NPs.
The TCL1-tg mouse represented an excellent model for testing in vivo delivery efficiency. We quantitatively investigated the delivery of 100 μg of miR-181b in different organs of FVB-TCL1 transplanted mice. Mice were treated when they exhibited a lymphocyte disease burden of 30-50% as the percentage of leukemic cells in peripheral blood. We tested CD38-NPs, nonconjugated NPs, or Jet-PEI, a formulation used in our previous study, 28 in four mice for each condition. The nanoparticles were administered by i.p. injection. After 24 h, mice were killed and organs collected. Total RNA was isolated from liver, splenocytes, heart, kidneys, thyroid, lungs, muscle, stomach, intestine, brain and bladder and the expression levels of miR-181b were quantified by digital PCR (Figure 2a) . Spleen was the most efficiently targeted organ by CD38-NPs, followed by liver. Compared with the physiological levels in these organs, the amount of miR-181b increased more than 300-fold following CD38-NP-mediated delivery. In splenocytes, CD38-NPs induced an 18-fold increase compared with Jet-PEI and a 3-fold increase compared with non-conjugated NPs (Figure 2b ). All other organs exhibited increased expression levels of miR-181b, generally at lower levels and independent to the type of NP.
The greater delivery mediated by CD38-NPs in spleen and liver of diseased animals was likely attributable to the presence of a high number of CD38+ cells. This conclusion was supported by the finding that no significant difference of miR-181b in spleen and liver was observed between CD38-NPs and non-conjugated NPs delivery efficacy when experiment was performed in FVB WT mice (Supplementary Figure 2) . These findings indicated that CD38-NPs were capable of improving efficiency of delivery and specificity of targeting for CD38+ CLL cells.
miR-26a, miR-130a and anti-miR-155 are selected as potential antileukemic molecules After the delivery efficacy of CD38-NPs was verified in vivo and in vitro, we tested the potential anti-leukemic effects of a group of selected miRNAs/anti-miRNAs.
From the results of our previous microRNAome study in human CLL, 27 we selected a group of miRNAs that were deregulated in human CLL. Herein, we tested miRNA mimics miR-15, miR-16, miR-26a, miR-125a, miR-130a and miR-34a or AMOs of miR-21, miR-155 and miR-130a. A scrambled RNA oligo was used as a negative control.
First, we investigated the in vitro biological activity on leukemic splenocytes isolated from the spleen of Eμ-TCL1FL transgenic mice. Leukemic splenocytes were transfected by the use of CD38-NPs and 48 h after transfection, apoptotic activity was assessed by Annexin V assay ( apoptotic activity was detected in splenocytes treated with miR-26a, miR-125a, anti-miR-155 and miR-130a (P o0.05). The efficiency of transfection of mimics/AMOs was assessed and confirmed in all the samples by analyzing the expression levels of each miRNA ( Figure 3b ).
Next, for in vivo studies, we first evaluated if the CD38-NPs could also mediate a more effective functional outcome than nonconjugated NPs. Given the high pro-apoptotic activity demonstrated in vitro, we selected the miR-26a for measuring in vivo biological effects. One hundred micrograms of miR-26a mimics was delivered into mice with a high disease burden (30-50% TCL1+ cells in peripheral blood) by using either CD38-NPs or nonconjugated NPs (three mice in each group). As control, three mice with a similar disease burden were treated with a scrambled RNA oligo. After 48 h from treatment (i.p. injection), mice were killed and splenocytes isolated to analyze the biological effects. As shown in Figure 4 , in comparison with non-conjugated NPs, the use of CD38-NPs induced a more effective downregulation CDK6, a target of miR26a, and a clearer activation of apoptosis, detectable by cleavage of PARP.
Based on these results, we evaluated a number of miRNA mimics/AMOs for their in vivo biological activity using CD38-NPs as delivery vehicles. Transplanted mice with a high disease burden (30-50% TCL1+ cells in peripheral blood) were treated with 100 μg of different miRNA mimics or AMOs (at least three mice in each group) by using CD38-NPs; as control, four mice with a similar disease burden were treated with scrambled miRNA. After 48 h of a single treatment (i.p. injection), mice were killed and splenocytes isolated to analyze the effects of miRNAs on apoptosis by the Annexin V assay. As shown in Figure 5a , treatment with miR-26a or miR-130a mimics or with anti-miR-155 oligonucleotides induced a significant increase in apoptotic cells compared with control (P o 0.05), while several other miRNAs did not exhibit significant differences. Notably, CD38-NP-Empty-treated mice exhibited a negligible effect in comparison with control (P = 0.6). The efficiency of delivery of mimic/AMOs in splenocytes was confirmed by quantitative PCR in all samples (Figure 5b ). These results revealed the potential pro-apoptotic activity of miR-26a, miR-130a and anti-miR-155 against leukemic cells. miR-26a reduces the expansion of leukemic cells of Eμ-TCL1 mice Given the observed pro-apoptotic effects after short-term treatments in vitro and in vivo, we sought to assess the potential antileukemic activity of miR-26a, miR-130a or anti-miR-155 after 3 weeks of treatment. We performed the experiments by using Figure 4 . CD38-NPs mediate an in vivo more effective functional outcome than non-conjugated NPs. Forty-eight hours after a single injection of miR-26a mimics (100 μg) with CD38-NPs or nonconjugated NPs, mice with established leukemia were killed, splenocytes were isolated and analyzed for RNA and protein expression. CD38-NP-miRNA26a produced a higher level of miR-26a than NP-miR26a. The results are shown as relative expression of miR-26a normalized to SNO412 expression, as measured by ddPCR. As a result, the treatment with CD38-NPs could mediate more effective functional outcomes as revealed by a clearer apoptotic effect (cleavage of PARP) and a stronger down regulation of a miR-26a target (CDK6). FVB WT mice transplanted with Eμ-TCL1FL leukemic cells as we have previously described. 28 Syngeneic transplantations were performed in 6-week-old mice by i.p. injection of 5 × 10 5 splenocytes, collected from an Eμ-TCL1FL transgenic mouse with advanced disease. We monitored the progression of leukemia in transplanted syngeneic mice over time by quantitatively measuring the increase of the human TCL1 transgene, using a biomarker of transplanted leukemic cells, in DNA isolated from peripheral blood with digital PCR.
Mice were enrolled for treatment at about 8 weeks after transplantation, when leukemic cells reached 15-30% of peripheral blood lymphocytes. At this stage, mice were assigned to five groups of treatment with the same schedule of administration (i.p. injection of 100 μg of miRNA mimics or AMOs three times a week for 3 weeks): (1) miR-26a, (2) miR-130a, (3) anti-miR-155, (4) scrambled oligo control and (5) CD38-NP-Empty nanoparticles. At the beginning of treatment, each group of mice exhibited the same or a very similar arithmetic mean and standard deviation of leukemic burden.
Before starting the treatments and 48 h after the last treatment, we measured by digital PCR and FACS analysis the percentage of B220+/CD5+ leukemic cells present in the blood. Results of the two assays were in agreement. The differences between percentages of leukemic cells before and after treatment are shown in Figure 6 . miR-26a treatment was the most effective in reducing the accumulation/expansion of leukemic cells in blood. The other molecules also induced a reduction of the leukemic cell burden in blood, albeit to a significantly less extent ( Figure 6 ). miR-26a promotes apoptosis in CLL cells Given the significant anti-leukemic effect of miR-26a, we investigated the effect of miR-26a on leukemic splenocytes after 3 weeks of in vivo treatment.
The activation of apoptosis was clearly detectable by analysis of poly(ADP-ribose) polymerase (PARP) and caspase-7: the appearance of the 85-kD fragment (cleaved PARP), together with the strong increase in cleavage of caspase-7 were seen only in mice treated with CD38-NP-miR-26a, thus indicating the induction of apoptosis (Figure 7a ).
To confirm that the apoptotic effect could be attributable to miR-26a activity, we analyzed the levels of two of its targets, Mcl1 and cyclin-dependent kinase 6 (Cdk6). Treatment with CD38-NPmiR-26a induced their downregulation, thus confirming the molecular activity of the delivered miR-26a (Figure 7b ).
DISCUSSION
The aim of this study was to demonstrate that miRNA-based therapies may have a place in the treatment of CLL, a human leukemia that is still incurable despite recent multiple successes. Our approach was based on evidence related to aberrant expressions of miRNA in CLL and on numerous observations. 19, 23, 25, 27, 33 To address the working hypothesis, we adopted the Eμ-TCL1 mouse model, which develops a leukemia that is highly similar to an aggressive form of human CLL. 15, 16 Using this model, we previously reported the anti-leukemic activity of miR-181b mimics. 28 Here, we assayed miR-15a, miR-16-1, miR-26a, miR-125a, miR-130a, miR-34a, ant-miR-130a, anti-miR-21 and anti-miR-155. Among these, miR-26a, miR-130a and anti-miR-155 induced apoptosis in leukemic cells both in vitro and in vivo in short-term assays. On the basis of these results, we tested the ability of miR-26a, miR-130a and anti-miR-155 to counteract the in vivo accumulation/expansion of leukemic cells of the Eμ-TCL1 mouse model. miR-155 is a well-known oncomiR. [34] [35] [36] [37] [38] [39] In human CLL, a high level of miR-155 was associated with various adverse prognostic factors. 27, [40] [41] [42] [43] Overexpression of miR-155 in transgenic mice was shown to induce polyclonal B-cell expansion. 34 The use of antimiR-155 molecules has been reported to significantly decrease Figure 6 . miR-26a exhibits the strongest activity against Eμ-TCL1FL leukemic cells. Percentages of circulating leukemic cells were measured just before starting treatments and 48 h after their completion. The differences between these points were acquired and plotted for each mouse enrolled in the study. miR-26a exhibited the strongest effect on expansion of leukemic burden, as shown in the graph and by the P-values in the associated table. P-valueso 0.05 are highlighted by a gray background. N, number of mice; s.d. = standard deviation. in vivo tumor growth of BCWM1 cells derived from a patient with Waldenstrom macroglobulinemia. 44 The role of miR-130a in tumorigenesis is, on the other hand, controversial. Various reports have indicated either tumor-suppressive [45] [46] [47] [48] [49] [50] [51] or oncogenic [52] [53] [54] [55] [56] activity, depending on the experimental settings. In human CLL, miR-130a was shown to repress a survival autophagic pathway by targeting ATG2B and DICER1. 57 No animal models are available to examine the physiological or pathological function of miR-130a. Similarly, contrasting results of dysregulated miR-26a have been reported in different tumor types. [58] [59] [60] For example, it was shown that miR-26a could facilitate glioblastoma formation in vivo, 58, 61 but it was also shown that low miR-26a expression conferred a shorter overall survival in liver cancer patients 62 and that its delivery through an adeno-associated viral vector could achieve a therapeutic effect on a MYC-induced liver cancer mouse model. 59 In human CLL, a tumor suppressive function of miR-26a was supported by evidence that its low expression was associated with a shortened time from diagnosis to first treatment, 27 a clinical feature associated with poor prognosis.
Despite the limited evidence linking miR-26a to CLL pathogenesis, this miRNA exhibited the strongest activity against the accumulation/expansion of leukemic cells by enhancing apoptosis. Several studies have previously documented that miR-26a is able to target and down-modulate several protein-coding gene targets, including CDK6, cyclins D2/E2 and Mcl-1, in different tumor cells. 59, [63] [64] [65] Here, we found that a strong apoptotic effect was detectable in the spleen of treated mice and proof of miR-26a activity was confirmed by the downregulation of two of its known targets, Mcl1 and Cdk6. The concomitant downregulation of the anti-apoptotic Mcl1 and the cell cycle-promoting Cdk6 proteins suggests not only that miR-26a can promote apoptosis, but that it can also inhibit CLL cell proliferation.
A second important result of this study was the development of nanoparticles conjugated with anti-CD38 antibodies that could efficiently deliver miRNA or AMOs into CD38+ cells, which typically characterize the most aggressive forms of CLL 29 and other hematological diseases such as myeloma. In fact, efficient, specific and safe delivery of miRNA mimics or AMOs is a major challenge in miRNA-based therapeutic applications. 66, 67 Currently, methods for miRNA systemic delivery are mainly designed to target the liver 68, 69 and they may use either viral 59, 70, 71 or non-viral systems. [72] [73] [74] [75] [76] Significant therapeutic effects in murine liver cancer models have been described. 59, 70, 77 More difficult, however, is the systemic delivery of miRNA mimics to other organs or tissues. Regarding hematopoietic cells, in vivo delivery of antagomiR-126 was achieved in acute myeloid leukemia subpopulations by using lipopolyplex nanoparticles conjugated with transferrin or antibody (anti-CD45.2). 72 The chemical and physical characteristics of this formulation were shown to bypass hepatic uptake and ultimately achieve better delivery to hematopoietic organs. 32 An analogous system based on stable nucleic acid lipid vesicles conjugated with transferrin was developed to target multiple myeloma cells expressing transferrin receptors. 78, 79 To develop a method for in vivo delivery to CLL cells, here we produced lipid nanoparticles, based on the formulation by Huang et al., 32 conjugated with an anti-CD38 antibody, whose antigen is present on the surface of leukemic cells of Eμ-TCL1 mouse model. Delivery to leukemic cells was superior to that of either nonconjugated nanoparticles or JetPEI, the nanosystem that we used in our previous report. 28 The presence of the anti-CD38 antibody conferred specificity of action and also led to internalization of the nanoparticle complex in targeted leukemic spleen cells. The internalization was previously shown by using a panel of rat and mouse-anti CD38 mAbs. 31 The results indicated that the adopted methodology is efficient in transferring a cargo of different miRNAs to leukemic cells. This competence was maintained in vivo. Spleen and liver were the most efficiently targeted organs by CD38-NPs. A small increase of miR-181b was also detectable in other organs, especially when non-conjugated nanoparticles were used. Since diseased mice are characterized by spleno-and hepatomegaly, these results strongly suggested that the CD38-NPs could increase delivery efficiency to these organs because they accumulate CD38+ CLL cells. The characteristics of CD38 targeting in terms of safety were recently confirmed in vivo in mAb-mediated therapy of human myeloma. 80 The main result of this study is that miR-26 exhibits a clear apoptotic effect on leukemic cells and a significant reduction in leukemic cell expansion, suggesting its consideration for future CLL therapy, possibly in combination with presently used therapeutic approaches. Moreover, we provide a novel delivery method, which improves the efficiency and specificity of miRNA delivery into CD38+ CLL cells. In humans, this approach could help target not only CLL cells in lymphatic organs, but also other CD38+ B-cell malignancies, including various types of lymphoma, plasma cell-derived neoplasms, and acute myeloid leukemia of the t(6;9) subtype. [81] [82] [83] [84] [85] [86] 
MATERIALS AND METHODS

Cell cultures and transfections
Mouse splenocytes were freshly isolated from diseased mice by using the procedure described by Bresin et al. 28 Transient transfections were performed with 100 nM pre-miR (Ambion, Waltham, MA, USA) or singlestranded anti-miRNA (IDT) or scrambled negative controls complexed with lipidic nanoparticles (NPs or CD38-NPs). Cells were collected 48 h after transfection to evaluate apoptosis and miR expression.
Mice and syngeneic transplantation
The TCL1-tg mouse model used for these experiments has been previously described. 15 Breeding pairs were provided to our group as a generous gift from C.M. Croce (Ohio State University). FVB WT mice were obtained from Charles River Laboratories (Wilmington, MA, USA). Mice had ad libitum access to water and a pellet diet. The animal room was maintained at 23°C on a 12-h light/12-h dark cycle. At the age of 6 weeks, the WT FVB female mice were transplanted by i.p. injection of 5 × 10 5 lymphocytes isolated from the spleen of an adult TCL1-tg mouse with established leukemia. The engraftment of leukemic cells and the progression of disease were monitored over time by the expression of B220/CD5 using flow cytometry analysis (FACS) or absolute quantification of the human TCL1 transgene by digital PCR of peripheral blood DNA. In order to comply with the 2010/63/EU directive of the European Parliament and Council, enforced by the Italian law, which requires that the number of experimental animals be minimized, for long-term experiments, G*Power (http://www.gpower.hhu.de/) was used to define sample size. For short-term experiments, the smallest number of mice sufficient to perform statistical analyses was used. All animals were randomly assigned to different treatment groups at the start of the studies. The protocol for animal experimentation was approved by the Italian Ministry of Health (approval n. 40-2014 PR released on 6 November 2014).
Anti-CD38 monoclonal antibody
The anti-CD38 antibody is a rat monoclonal antibody (mAb) specific for mouse CD38 antigen. It was prepared in the laboratory of one of the authors (FM, University of Turin). The hybridoma lines was a kind gift of Dr. Frances Lund, University of Alabama at Birmingham, AL. The NIMR-5 clone was expanded in vitro in Iscove's modified Dulbecco's medium and purified by high pressure liquid chromatography. The purified IgG was then sterilized by 0.22-μm filtration (Millipore Polyethersulfone Millex-GP Syringe Filter Unit, radiosterilized) and detoxified by Detoxi-Gel Endotoxin Removing Gel (Thermo Fisher Scientific, Waltham, MA, USA). 87 Specificity was confirmed by reacting the purified mAb with the murine 300.19/HLY-9 pre-B cell line and analyzing binding by indirect immunofluorescence. 87 
Preparation of nanoparticles
The lipid components of the nanoparticles were 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dimyristoyl-sn-glycerol, methoxypolyethylene glycol (MW~2000; DMG-PEG; Avanti Polar Lipids, Alabaster, AL, USA), and linoleic acid (Sigma-Aldrich, St Louis, MO, USA). The molar Anti-leukemic activity of microRNA-26a in CLL L D'Abundo et al ratio of DOPE:linoleic acid:DMG-PEG was 50:48:2. The preparation of empty nanoparticles was performed as previously described. 32 The anti-CD38 antibody was conjugated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide (polyethylene glycol)-2000] (DSPE-PEG2000 maleimide) according to the method described in a previous study 72 and was then post-inserted into the surface of lipopolyplex nanoparticles to form the CD38-NP-miRs.
In vivo treatment with mimics or AMOs
The synthetic mimics and anti-miRNAs for in vivo delivery were purchased from Axolab (Kulmbach, Germany). For short-term experiments, the FVB mice (at least three mice in each group) were randomly enrolled for treatment when the disease reached 30-50% of TCL1-positive cells in peripheral blood, and they were treated once with 100 μg of specific singlestrand mimics/anti-miRNA and killed after 48 h. For long-term experiments, the mice (at least six mice in each group) were randomly enrolled for treatment when the disease reached 15-30% of TCL1-positive cells in peripheral blood, and they were treated with 100 μg of the specified molecules three times a week for 3 weeks. For long-term treatments, the levels of disease were measured by FACS and droplet digital PCR (ddPCR) analysis the day before the start of treatment and 48 h after it ended.
Flow cytometry
Blood samples (20 μl) were placed in a tube containing 0.5 M ethylenediaminetetraacetic acid as an anticoagulant. Erythrocytes were lysed by treatment with ammonium chloride (0.8%) and ethylenediaminetetraacetic acid (0.1 mM) (Sigma). Cells were incubated with specific antibodies for 10 min in ice, washed and analyzed by flow cytometry in a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA, USA) by using FlowJo software (TreeStar, Ashland, OR, USA). Data for 5 × 10 4 cells within the lymphocyte light-scatter gate were collected. In these assays, color compensation was performed before cell acquisition by using the MACS Comp Bead Kit, anti-rat Igκ (Miltenyi Biotec, Gladbach, Germany). During analysis, gates were set by using a Fluorescence Minus One control strategy. Leukemic cells were identified as B220+/CD5dim cells, normal B lymphocytes as B220+/CD5 − cells, and T lymphocytes as B220 − /CD5+ cells. The following antibodies were used: FITC rat anti-mouse CD5 (Cat. 553020, BD Pharmingen, San Jose, CA, USA) and PeCy5 rat anti-mouse CD45R/B220 (Cat. 553091, BD Pharmingen). CD38 expression on the surface of leukemic splenocytes was detected by triple staining using a PE rat anti-mouse CD38 antibody (Cat. 130-103-008, Miltenyi Biotec) together with the FITC rat anti-mouse CD5 and the PeCy5 rat anti-mouse CD45R/ B220 antibody indicated above.
Analysis of apoptosis
The apoptotic effect of mimic or anti-miR molecules on murine splenocytes treated in vitro or in vivo was assessed by the Muse Annexin V 
Reverse transcription and ddPCR
The ddPCR method was used to measure the expression level of miRNAs. The reverse transcription reaction was performed on 5 ng of total RNA by using the TaqMan miRNA Reverse Transcription assay. After appropriate dilution, 1 μl of the cDNA was used for amplification in a 20-μl reaction volume containing ddPCR Supermix for Probes (Bio-Rad, Hercules, CA, USA) and the TaqMan miRNA PCR probe set. Droplets generation, cycling conditions for TaqMan assays and the counting of positive droplets were performed according to procedures described by Miotto et al. 88 To normalize the relative abundance of miRNAs, we used the Taqman Assays for RNAs U6 or SNO412 (Applied Biosystems, Foster City, CA, USA).
Monitoring leukemic cells by ddPCR
A ddPCR approach was used to measure the human TCL1 transgene in DNA extracted from peripheral blood cells of FVB transplanted mice. We used primers/probes specific for the human TCL1 transgene (forward 5′-CT CTGGCTCTTGCTTCTTAG-3′; reverse 5′-CACCCGTAACTGTAACCTATC-3′; probe--/56-FAM/TCGTGTATT/Zen/TGGACGAGAAGCA GCA/3IABkFQ/) and primers/probes specific for the mouse Gapdh gene as an endogenous reference (forward 5′-GGTGTGAACCACGAGAAATA-3′; reverse 5′-CTCAT GGCAGGGTAAGATAAG-3′; probe--/5HEX/ACAAC TTTG/Zen/GCATTGTGG AAGGGC/3IABkFQ/). The probes for human TCL1 and mouse Gapdh were conjugated with FAM and HEX, respectively. The ddPCR assay was performed on 10 ng of genomic DNA, using the same procedures as described above.
Western blot analysis
Splenocytes of treated and control mice were suspended in radioimmunoprecipitation assay buffer (Sigma-Aldrich), supplemented with protease and phosphatase inhibitors (Sigma-Aldrich), according to the manufacturer's protocol. Protein concentrations were measured with the Bradford assay (Bio-Rad). Equal amounts (30 μg) of protein extracts from all samples were applied to SDS-PAGE electrophoresis and then transferred to a PVDF membrane (Bio-Rad). The membrane was incubated with primary antibodies as follows: anti-CDK6 (rabbit, Cat. sc177, Santa Cruz Biotechnology, Dallas, TX, USA), anti-Mcl-1 (Rabbit, Cat.5453, Cell Signaling, Danvers, MA, USA), anti-PARP (rabbit, Cat. 9542, Cell Signaling), anti-caspase-7 (rabbit, Cat. 9492, Cell Signaling) 1:1000. β-Tubulin H235 (rabbit, Cat. sc9104, Santa Cruz Biotechnology), was used as a normalized control. The membrane was incubated with anti-rabbit IgG, horseradish peroxidase-linked antibody (Cat. 7074, Cell Signaling). For signal detection, Clarity Western ECL Substrate (Cat. 170-5060, Bio-Rad) was used according to the manufacturer's instructions. Digital images were acquired with Chemidoc (Bio-Rad). Signals were quantified by ImageJ software and protein expression levels normalized according to β-tubulin expression.
Statistical analyses
Reported data are expressed as mean ± s.d.; the calculated t-test or t-test with Welch's correction when required were considered statistically significant at P-valueo0.05. Variances between groups were evaluated by the F-test. Graphpad Prism 6.0 software was used for data analysis. No samples or animals were excluded from the analyses. None of the investigators were blinded to group allocations.
